Physician profile
Cory L Calendine
NPI 1417973249
$2,518,923.37
in general payments reported to CMS, 2019-2025
19 companies · $784K in 2025
The $784K reported for 2025 was more than what 98% of Adult Reconstructive Orthopaedic Surgery providers received nationally (typical 2025 total: $1,425).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $196K · 2020: $333K · 2021: $354K · 2022: $232K · 2023: $291K · 2024: $328K · 2025: $784K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $700K · Royalty Or License: $549K · Travel and Lodging: $140K · Food and Beverage: $11K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $2,500 · Honoraria: $900 · Education: $141 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $699,584.35 |
| Royalty Or License | $548,619.33 |
| Travel and Lodging | $140,261.79 |
| Food and Beverage | $10,798.62 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $2,500.00 |
| Honoraria | $900.00 |
| Education | $140.53 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $100.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $2,500,347.84 | 2019-2025 | Mako, Insignia, Triathlon |
| Vertex Pharmaceuticals Incorporated | $12,224.65 | 2024-2025 | |
| Henry Schein, INC. | $2,500.00 | 2024 | |
| Davol INC. | $923.22 | 2024 | Arista Ah Flexitip |
| Medtronic USA, INC. | $848.70 | 2020 | |
| Endo Pharmaceuticals INC. | $580.00 | 2024 | |
| Hikma Pharmaceuticals USA | $423.20 | 2024 | Combogesic IV |
| Innovation Technologies INC | $195.31 | 2024-2025 | Irrisept |
| Conformis, INC. | $127.86 | 2020-2022 | |
| Ethicon US, LLC | $126.43 | 2025 | Stratafix |
| Zimmer Biomet Holdings, INC. | $116.11 | 2019-2021 | |
| Exactech, INC. | $109.56 | 2019 | |
| Restor3d, INC. | $102.05 | 2023 | |
| Medacta USA, INC. | $100.00 | 2021 | |
| Think Surgical, INC. | $84.18 | 2024 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heron Therapeutics, INC. | $62.74 | 2024 | Aponvie, Zynrelef |
| Solventum Corporation | $18.98 | 2024 | Prevena |
| Avanos Medical | $17.05 | 2019 | |
| Medical Device Business Services, INC. | $15.49 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cory Calendine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.